Loading
Hypertension is both a cause and a consequence of CKD. The KDIGO blood pressure targets, the medications that protect kidneys, and how to measure BP properly.
Evidence reviewed & updated: 2026-08 — reflects the latest published trials and guidelines.
Hypertension is the #2 cause of kidney failure in the US and India — and kidney disease itself raises blood pressure. KDIGO 2021 targets office systolic BP below 120 mmHg in CKD, using ACEi/ARB as first-line (especially with albuminuria), plus SGLT2 inhibitors, sodium reduction, and home BP monitoring.
High pressure damages kidney blood vessels — glomerular hypertension and ischemia drive nephron loss. In the other direction, failing kidneys retain sodium and water and over-activate the renin-angiotensin system, raising BP further. The loop is why BP control is the most powerful single intervention in CKD: every 5 mmHg systolic reduction measurably slows progression.
Proteinuria and BP interact: ACEi/ARB reduce both intraglomerular pressure and albuminuria — the two pillars of kidney protection work together.
KDIGO 2021 recommends office systolic below 120 mmHg for most adults with CKD — stricter than the general population. Achieving it usually takes multiple agents: ACEi or ARB first-line (with albuminuria), then a calcium channel blocker or diuretic, with SGLT2 inhibitors added for cardiorenal protection.
Home BP monitoring matters: office readings overestimate control. Standard technique: seated 5 minutes, cuff at heart level, morning and evening readings averaged over a week. White-coat hypertension is common in CKD.
ACEi/ARB: first-line, especially with albuminuria; the initial creatinine rise of 10-30% is expected and protective (check at 1-2 weeks; don't stop unless it exceeds 30% or potassium rises dangerously). SGLT2i: add for cardiorenal protection — they lower BP modestly and protect kidneys. Calcium channel blockers and thiazide/loop diuretics complete the stack as needed.
What to avoid: NSAIDs (raise BP, blunt ACEi/ARB, cause AKI — the 'triple whammy' with diuretics), high sodium, and alcohol excess. Target sodium under 2 g/day — the most effective non-drug lever.
RAS blockade (ACEi or ARB) is the foundational renoprotective therapy for proteinuric CKD — proven in RENAAL (losartan, ...
Learn moreSGLT2 inhibitors (dapagliflozin, empagliflozin) are the most impactful CKD therapy advance in a decade. DAPA-CKD (NEJM 2...
Learn moreHeart failure and CKD are the defining comorbidity pair of modern nephrology: each causes and worsens the other (cardior...
Learn moreZuvFlo is ready to integrate with your facility to streamline operations, automate compliance, and deliver better patient care.
No credit card required • Setup in under 2 hours • Cancel anytime